ZURICH (Dow Jones) – Roche Holding AG is in terms of its drug pipeline optimistic. Several experimental Drugs are likely to reach the market potential for Billion in revenues have, as from a presentation by the Basel pharmaceutical company showing for an investor conference in New York.
Drug in clinical development, such as diabetes funds "Algelitazar" which Mutliple sclerosis treatment "ocrelizumab" or used in the treatment of schizophrenia Clycin uptake inhibitors (ClyT-) 1 inhibitor, could annually Reach peak sales of over 2 billion Swiss francs. The cholesterol drug "Dalcetrapib" with its annual sales could even mark for the C $ 5 billion . surpass
Website: www.roche.com -By Goran Mijuk, Dow Jones Newswires +49 (0) 69 29725 103, unternehmen.de @ dowjones.com DJG / DJN / sha / jhe Visit our website http://www.dowjones.de
(END) Dow Jones Newswires
March 18, 2010 10:32 ET (14:32 GMT)
Copyright (c) 2010 Dow Jones & Company, Inc
Tags: dow jones company, roche holding ag, dow jones company inc, dow jones newswires, goran mijuk
